Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 Recruiting
83 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Phase 3 Recruiting
60 enrolled
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Phase 3 Recruiting
247 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
MAHOGANY
Phase 3 Recruiting
780 enrolled
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Phase NA Recruiting
60 enrolled
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 Recruiting
1,875 enrolled
HOPAYA
Phase NA Recruiting
214 enrolled
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Phase 2 Recruiting
125 enrolled
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Phase 2 Recruiting
120 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
CaDAnCe-302
Phase 3 Recruiting
250 enrolled
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Phase 2 Recruiting
22 enrolled
CaDAnCe-303
Phase 3 Recruiting
150 enrolled
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 Recruiting
500 enrolled
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Recruiting
500 enrolled
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 Recruiting
65 enrolled
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Phase 1/2 Recruiting
196 enrolled
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
263 enrolled 2 FDA
PEACE
Phase NA Recruiting
90 enrolled
PRIMAVERA
Phase 1/2 Recruiting
161 enrolled
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Phase 3 Recruiting
600 enrolled
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1 Recruiting
12 enrolled
SOUNDTRACK-D2
Phase 3 Recruiting
420 enrolled
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Phase 1 Recruiting
54 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
132 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/2 Recruiting
45 enrolled
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2 Recruiting
56 enrolled
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Phase NA Recruiting
30 enrolled
waveLINE-003
Phase 2/3 Recruiting
290 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
121 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Phase 2 Recruiting
20 enrolled
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phase 1/2 Recruiting
90 enrolled
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 Recruiting
20 enrolled
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 Recruiting
222 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
85 enrolled
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
LIBERTY
Phase 3 Recruiting
104 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
MK-2140-011
Phase 2 Recruiting
594 enrolled
Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
Phase NA Recruiting
20 enrolled
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Phase 1 Recruiting
224 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled